Venous thromboembolism: not as easy as it looks

Johnson, Miriam J.
July 2009
British Journal of Hospital Medicine (17508460);Jul2009, Vol. 70 Issue 7, p374
Academic Journal
The author reflects on the risk of venous thromboembolism on patients with cancer in Great Britain. She notes that the risk of cancer patient developing venous thromboembolism is increased by many anti-cancer chemotherapies. She stresses that awareness of the complex interaction between cancer, its treatment and thrombosis is required to improve management for patients.


Related Articles

  • Patients with cancer at increased risk for thromboembolism. Raible, Eric // Cardiology Today;Jun2008, Vol. 11 Issue 6, p23 

    The article reports on the study made by Agnes Lee, associate professor of medicine at McMaster University in Ontario, suggesting that a regimen of dalteparin, which is a low-molecular-weight heparin, was effective at preventing recurrent thromboembolism in patients with cancer. This was...

  • Dalteparin reduced recurrent venous thromboembolism more than oral anticoagulation in patients with cancer: COMMENTARY. Deitcher, Steven R. // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p10 

    This article focuses on a study regarding low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism (VTE) in patients with cancer, published in the 2003 issue of "New England Journal of Medicine." In patients with cancer and VTE, long-term warfarin...

  • Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? a qualitative study. Johnson, Miriam J.; Sheard, Laura; Maraveyas, Anthony; Noble, Simon; Prout, Hayley; Watt, Ian; Dowding, Dawn // BMC Medical Informatics & Decision Making;2012, Vol. 12 Issue 1, p75 

    Background: The treatment of cancer associated thrombosis (CAT) is well established, with level 1A evidence to support the recommendation of a low molecular weight heparin (LMWH) by daily injection for 3-6 months. However, registry data suggest compliance to clinical guidelines is poor....

  • A prospective evaluation of venous thromboembolism in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Lanuke, Kathryn; Mack, Lloyd A.; Temple, Walley J. // Canadian Journal of Surgery;Feb2009, Vol. 52 Issue 1, p18 

    Background: We sought to investigate the incidence of perioperative venous thromboembolism (VTE) — pulmonary embolism, superior mesenteris vein thrombosis and deep vein thrombosis — in patients with peritoneal carcinomatosis after cytoreductive surgery combined with hyperthermic...

  • Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Palumbo, A.; Rajkumar, S. V.; Dimopoulos, M. A.; Richardson, P. G.; San Miguel, J.; Barlogie, B.; Harousseau, J.; Zonder, J. A.; Cavo, M.; Zangari, M.; Attal, M.; Belch, A.; Knop, S.; Joshua, D.; Sezer, O.; Ludwig, H.; Vesole, D.; Bladé, J.; Kyle, R.; Westin, J. // Leukemia (08876924);Feb2008, Vol. 22 Issue 2, p414 

    The incidence of venous thromboembolism (VTE) is more than 1‰ annually in the general population and increases further in cancer patients. The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide, especially in combination with dexamethasone or...

  • Cardio-oncology: A new focus for cardiovascular medicine. Hundley, W. Gregory // Hem/Onc Today;8/10/2011, Vol. 12 Issue 15, p20 

    The author reflects on the increased incidence of premature cardiovascular (CV) events in populations of cancer survivors in the U.S. as advances in treatment have reduced cancer-related mortality.

  • Recommandations pour la pratique clinique 2008: prise en charge de la thrombose veineuse chez les patients atteints de cancer (méthode SOR). Debourdeau, P.; Farge-Bancel, D.; Bosquet, L.; Kassab-Chahmi, D.; Cajfinger, F.; Desmurs-Clavel, H.; Desruennes, E.; Douard, M.-C.; Elias, A.; Elalamy, I.; Grange, C.; Hocini, H.; Kriegel, I.; Le Gal, G.; Lévesque, H.; Mahé, I.; Meyer, G.; Mismetti, P.; Pavic, M.; Quéré, I. // Oncologie;Dec2008, Vol. 10 Issue 12, p749 

    The “Standards, Options: Recommendations” (SOR) project has been initiated by the French National Federation of Cancer Centers (FNCLCC) and is now part of the French National Cancer Institute. The project aims to develop and update the evidence-based Clinical Practice Guidelines...

  • Does calf DVT really require anticoagulation? Hunt, Beverley // Pulse;5/7/2008, Vol. 68 Issue 16, p43 

    The article provides an answer to a question concerning venous thromboembolism.

  • Male childhood cancer survivors had greater adiposity, cardiovascular risk factors. Brannon, Matthew; Fisher, Stacey L.; Foster, Melissa; Moskowitz, Andrew // Infectious Diseases in Children;Oct2010, Vol. 23 Issue 10, p53 

    The article presents a research that found greater adiposity and cardiovascular risk factors in male childhood cancer survivors than female cancer survivors and healthy siblings.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics